March 08, 2013 at 11:02 AM EST
UPDATE: Canaccord Lowers PT on Hi-Tech Pharmacal Co. on F3Q EPS Miss
In a report published Friday, Canaccord Genuity reiterated its Buy rating on Hi-Tech Pharmacal Co. (NASDAQ: HITK ), but lowered its price target from $42.00 to $40.00. Canaccord Genuity noted, “HITK reported F3Q results that brought some cough-and-cold-driven revenue upside that was appropriately overshadowed by the cost-driven EPS miss. While
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here